NEWS RELEASE
	CONTACT:
	CONMED Corporation
	Robert Shallish
	Chief Financial Officer
	315-624-3206

 

 

 

FOR RELEASE: 7:00 AM (Eastern) February 14, 2013

 

CONMED Corporation Announces Fourth Quarter 2012 Financial Results

 

- Sales Increase 8.4%

- GAAP EPS of $0.38

- Adjusted EPS of $0.52

 

- Conference Call to be Held at 10:00 a.m. ET Today -

 

 

Utica, New York, February 14, 2013 ----- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the fourth quarter and year ended December 31, 2012.

 

“Strong earnings and cash flow were the hallmarks of CONMED’s fourth quarter results, completing 2012 with the best quarterly performance of the year,” commented Mr. Joseph J. Corasanti, President and CEO. Reported earnings per share grew to $0.38 from a loss of $0.90 in the fourth quarter of 2011. Adjusted for restructuring and unusual items, diluted earnings per share grew 13.0% to $0.52 compared to $0.46 in the same quarter of 2011. Free cash flow for the fourth quarter of 2012 was $28.4 million, more than two times the net income for the quarter. Reported sales growth was 8.4% (7.8% constant currency) while organic sales growth was 3.3% excluding MTF and Viking revenues.

 

Fourth Quarter 2012 Financial Highlights:

 

·

Sales grew to $201.2 million, an increase of 8.4% (organic increase of 3.3%) and an increase of 7.8% on a constant currency basis as compared to the fourth quarter of 2011.

 

·

Single-use products grew 10.7% and comprise 79.7% of total sales.

 

·

Diluted earnings per share (GAAP) grew to $0.38 compared to a loss of $0.90.

 

·

Adjusted diluted earnings per share grew 13.0% to $0.52.

 

·

Adjusted EBITDA margin expanded 110 basis points to 18.1%.

 

·

GAAP EBITDA margin was 14.3%.

 

·

A favorable income tax benefit amounting to $0.04 per share was recorded due to the conclusion of a tax matter.

 

·

The Board of Directors declared a quarterly cash dividend of $0.15 per share, which was paid on January 7, 2013.

 

CONMED News Release Continued

Page 2 of 12

February 14, 2013

 

Year 2012 Financial Highlights

 

·

Sales grew to $767.1 million, an increase of 5.8% (organic increase of 1.5%) and an increase of 5.7% on a constant currency basis as compared to 2011.

 

·

Single-use products grew 8.5% comprising 80.0% of total revenues, while capital products declined 3.9%.

 

·

Diluted earnings per share (GAAP) grew to $1.41 vs. $0.03 in 2011.

 

·

Adjusted earnings per share grew 20.0% to $1.80.

 

·

Adjusted EBITDA margin expanded 140 basis points to 17.4%.

 

·

GAAP EBITDA margin was 14.5%.

 

International sales in the fourth quarter and full year 2012 were $101.0 million and $384.9 million, respectively, or 50.2% total sales for both periods. The recent volatility in foreign currency exchange rates was mitigated by the Company’s currency hedging. Fourth quarter 2012 sales were higher by $1.1 million and the year’s sales were lower by $4.4 million than would have been the case using comparable 2011 exchange rates.

 

Cash provided by operating activities in the fourth quarter of 2012 amounted to $33.9 million. For the full year 2012, cash provided by operating activities totaled $95.2 million. This cash generation is 16.9% of sales for the fourth quarter and 12.4% of sales for the 2012 year.

 

As a component of the Company’s capital allocation strategy, CONMED has returned value to shareholders through the initiation in early 2012 of a 15 cent quarterly dividend (which provides a yield of approximately 2% based upon the current share price). Further, the Board of Directors has previously authorized share repurchases and the Company has purchased approximately $15.9 million of its shares on the open market since October 2012. It is management’s intention, subject to market conditions and provisions of its credit agreement, to additionally repurchase approximately $35 million of CONMED stock over the next three to six months as an additional means of returning value to the Company’s shareholders.

 

Outlook

 

“Our outlook for 2013 is unchanged from our communication in October last year. We reiterate the estimated $1.80 - $1.90 adjusted diluted earnings per share guidance for 2013 on estimated sales of $785 - $795 million. This guidance recognizes the negative effects of the 2.3% excise tax on medical devices and foreign currency exchange rates lower than the FX rates at which we hedged our sales in 2012. These headwinds amount to approximately $0.25 per share and would have resulted in adjusted EPS growth of 14.0% to 19.0% without their deleterious effects,” noted Mr. Corasanti.

 

“Effectively, these external matters have caused us to re-set the base from which management will target earnings growth of approximately 15% annually in-line with our strategic plan,” continued Mr. Corasanti. “For the first quarter of 2013, we expect sales will approximate $192 - $198 million and adjusted diluted earnings per share will be in the range of $0.42 - $0.47.”

 

The sales and earnings forecasts for 2013 have been developed using January 2013 currency exchange rates and take into account the currency hedges entered into by the Company.

 

The adjusted estimates for the first quarter and full year 2013 exclude unusual matters, such as the restructuring costs expected to be incurred due to the Viking acquisition and the consolidation of the Tampere, Finland location into United States facilities. Costs related to these consolidation activities are excluded from the estimates above.

 

 

CONMED News Release Continued

Page 3 of 12

February 14, 2013

 

Unusual charges

 

During 2012, the Company purchased Viking Systems, Inc., a developer of 3D-HD surgical video systems, continued the on-going consolidation of certain administrative functions, transferred additional product lines to its Mexican manufacturing facility and began the consolidation of the Tampere, Finland facility. Also incurred were integration costs relative to the purchase of a distributor in northern Europe and litigation costs associated with a contractual dispute with a former distributor. Expenses associated with these activities, including severance and relocation costs, amounted to $4.0 million, net of tax, in the fourth quarter of 2012 and $11.2 million net of tax for the year. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For 2013, the Company presently anticipates incurring additional pre-tax restructuring costs of $8.0 - $10.0 million on projects currently in process.

 

 

Use of non-GAAP financial measures

 

Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company’s on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income and adjusted earnings per share measure the income of the Company excluding unusual credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income and adjusted earnings per share because management believes that in order to properly understand the Company’s short and long-term financial trends, the impact of unusual items should be eliminated from on-going operating activities. These adjustments for unusual items are derived from facts and circumstances that vary in frequency and impact on the Company’s results of operations. Management uses adjusted net income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP. Please refer to the attached reconciliations between GAAP and adjusted financial measures.

 

Conference call

 

The Company will webcast its fourth quarter 2012 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, February 14, 2013. This webcast can be accessed from CONMED’s web site at www.conmed.com. Replays of the call will be made available through February 28, 2013.

 

CONMED profile

 

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company’s 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company’s total sales.

 

Forward Looking Information

 

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw materials or transportation (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company’s ability to devise and execute strategies to respond to market conditions.

 

CONMED News Release Continued

Page 4 of 12

February 14, 2013

CONMED CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(in thousands except per share amounts)

(unaudited)

 

		Three months ended								Twelve months ended
		December 31,								December 31,
		2011				2012				2011				2012
Net sales		$	185,577			$	201,244			$	725,077			$	767,140
Cost of sales			88,224				91,424				346,676				354,245
Cost of sales, other - Note A			901				2,533				3,467				7,052
Gross profit			96,452				107,287				374,934				405,843
Selling and administrative			70,325				79,892				276,615				302,469
Research and development			7,152				6,850				28,651				28,214
Other expense – Note B			300				3,529				1,092				9,950
Impairment of goodwill – Note C			60,302				—				60,302				—
			138,079				90,271				366,660				340,633
Income (loss) from operations			(41,627	)			17,016				8,274				65,210
Amortization of debt discount			565				—				3,903				—
Interest expense			1,494				1,397				6,676				5,730
Income (loss) before income taxes			(43,686	)			15,619				(2,305	)			59,480
Provision (benefit) for income taxes			(18,552	)			4,722				(3,057	)			18,999
Net income (loss)		$	(25,134	)		$	10,897			$	752			$	40,481
Per share data:
Net Income (loss)
Basic		$	(0.90	)		$	0.38			$	0.03			$	1.43
Diluted			(0.90	)			0.38				0.03				1.41
Weighted average common shares
Basic			27,933				28,408				28,246				28,301
Diluted			27,933				28,727				28,633				28,653

 

Note A - Included in cost of sales, other in the three and twelve months ended December 31, 2011 and 2012 are costs related to the consolidation of our production facilities. Refer to the Reconciliation of Reported Net Income to Non-GAAP Net Income Before Unusual Items and Amortization of Debt Discount for further details.

 

Note B – Other expense in the three and twelve months ended December 31, 2011 and 2012 includes a number of unusual charges. Refer to the Reconciliation of Reported Net Income to Non-GAAP Net Income Before Unusual Items and Amortization of Debt Discount for further details.

 

Note C - Impairment of goodwill is a non-cash charge related to the CONMED Patient Care business unit resulting from the Company’s yearly evaluation of intangible asset values in accordance with ASC 350.

 

 

CONMED News Release Continued

Page 5 of 12

February 14, 2013

  

 

CONMED CORPORATION

CONSOLIDATED CONDENSED BALANCE SHEETS

(in thousands)

(unaudited)

 

ASSETS

 

		December 31,
		2011				2012
Current assets:
Cash and cash equivalents		$	26,048			$	23,720
Accounts receivable, net			135,641				139,124
Inventories			168,438				156,228
Income tax receivable			—				191
Deferred income taxes			10,283				11,931
Other current assets			16,314				14,993
Total current assets			356,724				346,187
Property, plant and equipment, net			139,187				139,041
Deferred income taxes			2,389				1,057
Goodwill			234,815				256,821
Other intangible assets, net			195,531				190,809
Other assets			6,948				150,547
Total assets		$	935,594			$	1,084,462
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt		$	54,557			$	1,050
Other current liabilities			76,627				121,458
Total current liabilities			131,184				122,508
Long-term debt			88,952				160,802
Deferred income taxes			92,785				107,518
Other long-term liabilities			49,602				86,636
Total liabilities			362,523				477,464
Shareholders' equity:
Capital accounts			244,980				256,672
Retained earnings			354,439				377,907
Accumulated other comprehensive loss			(26,348	)			(27,581	)
Total equity			573,071				606,998
Total liabilities and shareholders' equity		$	935,594			$	1,084,462

 

 

CONMED News Release Continued

Page 6 of 12

February 14, 2013

  

CONMED CORPORATION

CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS

(in thousands)

(unaudited)

		Twelve months ended
		December 31,
		2011				2012
Cash flows from operating activities:
Net income		$	752			$	40,481
Adjustments to reconcile net income
to net cash provided by operating activities:
Depreciation and amortization			42,687				46,616
Stock-based compensation expense			5,240				5,653
Deferred income taxes			(13,098	)			12,946
Impairment of goodwill			60,302				—
Increase (decrease) in cash flows from changes in assets and liabilities:
Accounts receivable			8,464				1,687
Inventories			(7,850	)			3,810
Accounts payable			2,649				259
Income taxes			4,672				(6,651	)
Accrued compensation and benefits			1,673				767
Other assets			(4,243	)			(1,210	)
Other liabilities			1,745				(9,159	)
Net cash provided by operating activities			102,993				95,199
Cash flows from investing activities:
Purchases of property, plant, and equipment, net			(17,552	)			(21,532	)
Proceeds from sale of property			—				1,836
Payments related to business acquisitions and distribution agreements, net of cash acquired			(4,191	)			(86,253	)
Net cash used in investing activities			(21,743	)			(105,949	)
Cash flows from financing activities:
Payments on debt			(114,010	)			(54,657	)
Proceeds of debt			58,000				73,000
Net proceeds from common stock issued under employee plans			6,117				10,165
Dividend payments on common stock			—				(12,862	)
Repurchase of common stock			(15,021	)			(3,923	)
Other, net			(1,785	)			(370	)
Net cash provided by (used in) financing activities			(66,699	)			11,353
Effect of exchange rate change on cash and cash equivalents			(920	)			(2,931	)
Net increase (decrease) in cash and cash equivalents			13,631				(2,328	)
Cash and cash equivalents at beginning of period			12,417				26,048
Cash and cash equivalents at end of period		$	26,048			$	23,720

 

 

 

 

CONMED News Release Continued

Page 7 of 12

February 14, 2013

 

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME

BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT

Three Months Ended December 31, 2011 and 2012

(In thousands except per share amounts)

(unaudited)

 

		2011				2012
Reported net income (loss)		$	(25,134	)		$	10,897
Facility consolidation costs included in cost of sales			901				2,533
Administrative consolidation costs included in other expense			—				3,053
Viking acquisition costs included in other expense			—				476
Costs associated with purchase of Nordic region distributor			300				—
Total other expense			300				3,529
Impairment of goodwill			60,302				—
Amortization of debt discount			565				—
Total unusual expense before income taxes			62,068				6,062
Provision (benefit) for income taxes on unusual expense			(24,073	)			(2,074	)
Net income before unusual items and amortization of debt discount.		$	12,861			$	14,885
Per share data:
Reported net income (loss)
Basic		$	(0.90	)		$	0.38
Diluted			(0.90	)			0.38
Net income before unusual items and amortization of debt discount
Basic		$	0.46			$	0.52
Diluted			0.46				0.52

 

Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in previous releases which exclude such expense.

 

 

CONMED News Release Continued

Page 8 of 12

February 14, 2013

 

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME

BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT

Twelve Months Ended December 31, 2011 and 2012

(In thousands except per share amounts)

(unaudited)

 

 

		2011				2012
Reported net income		$	752			$	40,481
Facility consolidation costs included in cost of sales			3,467				7,052
Administrative consolidation costs included in other expense			792				6,497
Viking acquisition costs included in other expense			—				1,194
Costs associated with purchase of Nordic region distributor			300				704
Legal costs included in other expense			—				1,555
Total other expense			1,092				9,950
Impairment of goodwill			60,302				—
Amortization of debt discount			3,903				—
Total unusual expense before income taxes			68,764				17,002
Provision (benefit) for income taxes on unusual expense			(26,515	)			(5,829	)
Net income before unusual items and amortization of debt discount		$	43,001			$	51,654
Per share data:
Reported net income
Basic		$	0.03			$	1.43
Diluted			0.03				1.41
Net income before unusual items and amortization of debt discount
Basic		$	1.52			$	1.83
Diluted			1.50				1.80

 

Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in previous releases which exclude such expense.

 

 

CONMED News Release Continued

Page 9 of 12

February 14, 2013

 

CONMED CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(in thousands)

(unaudited)

 

		Three months ended								Twelve months ended
		Dec 31,								Dec 31,
		2011				2012				2011				2012
Reported income from operations		$	(41,627	)		$	17,016			$	8,274			$	65,120
Facility consolidation costs included in cost of sales			901				2,533				3,467				7,052
Administrative consolidation costs included in other expense			—				3,053				792				6,497
Viking acquisition costs included in other expense			—				476				—				1,194
Costs associated with purchase of Nordic region distributor			300				—				300				704
Legal costs included in other expense			—				—				—				1,555
Impairment of goodwill			60,302				—				60,302				—
Adjusted income from operations		$	19,876			$	23,078			$	73,135			$	82,122
Operating margin
Reported (GAAP)			-22.4%				8.5%				1.1%				8.5%
Adjusted (non-GAAP)			10.7%				11.5%				10.1%				10.7%

 

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section “Use of non-GAAP financial measures” above.

 

 

CONMED News Release Continued

Page 10 of 12

February 14, 2013

 

 

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA

(in thousands)

(unaudited)

 

		Three months ended								Twelve months ended
		Dec 31,								Dec 31,
		2011				2012				2011				2012
Net income		$	(25,134	)		$	10,897			$	752			$	40,481
Provision for income taxes			(18,552	)			4,722				(3,057	)			18,999
Interest expense			1,494				1,397				6,676				5,730
Depreciation			4,817				4,617				18,519				18,635
Amortization of debt discount			565				—				3,903				—
Amortization, all other			5,273				7,100				19,105				27,305
EBITDA (using GAAP measures)		$	(31,537	)		$	28,733			$	45,898			$	111,150
Stock-based compensation expense			1,526				1,538				5,240				5,653
Facility consolidation costs included in cost of sales			901				2,533				3,467				7,052
Administrative consolidation costs included in other expense			—				3,053				792				6,497
Viking acquisition costs included in other expense			—				476				—				1,194
Costs associated with purchase of Nordic region distributor			300				—				300				704
Legal costs included in other expense			—				—				—				1,555
Impairment of goodwill			60,302				—				60,302				—
Adjusted EBITDA		$	31,492			$	36,333			$	115,999			$	133,805
EBITDA Margin
EBITDA (using GAAP measures)			-17.0%				14.3%				6.3%				14.5%
Adjusted EBITDA (using non-GAAP measures)			17.0%				18.1%				16.0%				17.4%

 

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section “Use of Non-GAAP Financial Measures” above.

 

CONMED News Release Continued

Page 11 of 12

February 14, 2013

CONMED CORPORATION

Fourth Quarter Sales Summary

 

		Three Months Ended December 31,
														Constant
														Currency
		2011				2012				Growth				Growth
		(in millions)
Arthroscopy
Single-use		$	57.3			$	69.6				21.5%				20.6%
Capital			17.1				17.0				-0.6%				-1.2%
			74.4				86.6				16.4%				15.6%
Powered Surgical Instruments
Single-use			19.7				20.5				4.1%				3.0%
Capital			17.1				17.8				4.1%				3.5%
			36.8				38.3				4.1%				3.3%
Electrosurgery
Single-use			19.2				20.1				4.7%				4.7%
Capital			6.5				6.0				-7.7%				-7.7%
			25.7				26.1				1.6%				1.6%
Endoscopic Technologies
Single-use			12.6				13.4				6.3%				5.6%
Endosurgery
Single-use and reposable			19.0				19.9				4.7%				4.2%
Patient Care
Single-use			17.1				16.9				-1.2%				-1.8%
Total
Single-use and reposable			144.9				160.4				10.7%				10.0%
Capital			40.7				40.8				0.2%				-0.2%
		$	185.6			$	201.2				8.4%				7.8%

 

 

 

CONMED News Release Continued

Page 12 of 12

February 14, 2013

 

CONMED CORPORATION

Year Sales Summary

 

 

		Year Ended December 31,
														Constant
														Currency
		2011				2012				Growth				Growth
		(in millions)
Arthroscopy
Single-use		$	226.9			$	267.4				17.8%				17.7%
Capital			63.0				63.1				0.2%				0.8%
			289.9				330.5				14.0%				14.0%
Powered Surgical Instruments
Single-use			78.5				82.4				5.0%				4.9%
Capital			69.4				67.6				-2.6%				-2.7%
			147.9				150.0				1.4%				1.3%
Electrosurgery
Single-use			71.1				72.8				2.4%				2.4%
Capital			27.5				22.9				-16.7%				-17.0%
			98.6				95.7				-2.9%				-3.0%
Endoscopic Technologies
Single-use			49.3				53.2				7.9%				7.5%
Endosurgery
Single-use and reposable			73.7				74.0				0.4%				0.1%
Patient Care
Single-use			65.7				63.7				-3.0%				-3.0%
Total
Single-use and reposable			565.2				613.5				8.5%				8.4%
Capital			159.9				153.6				-3.9%				-3.8%
		$	725.1			$	767.1				5.8%				5.7%